T1	HMM 196 215	efficacy and safety
T2	HMM 708 736	end-point was the difference
T3	HMM 782 997	end-points were differences in daily mean: (i) voiding frequency at 4 and 8Â weeks; (ii) urgency frequency; (iii) urgency incontinence frequency; (iv) incontinence frequency; (v) nocturia frequency; and (vi) quality
T4	HMM 1013 1132	The variables for safety analysis were adverse events, vital signs, residual urine volume and clinical laboratory tests
T5	HMM 1272 1283	differences
